Gamco Investors INC. ET AL Has $2.22 Million Holdings in Evolent Health, Inc. (NYSE:EVH)

Gamco Investors INC. ET AL grew its holdings in shares of Evolent Health, Inc. (NYSE:EVH - Free Report) by 43.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 197,100 shares of the technology company's stock after buying an additional 60,000 shares during the quarter. Gamco Investors INC. ET AL owned 0.17% of Evolent Health worth $2,217,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in EVH. Pilgrim Partners Asia Pte Ltd acquired a new stake in shares of Evolent Health during the 4th quarter valued at approximately $26,000. R Squared Ltd acquired a new stake in shares of Evolent Health during the 4th quarter valued at approximately $31,000. AlphaQuest LLC raised its position in shares of Evolent Health by 21,650.0% during the 4th quarter. AlphaQuest LLC now owns 3,045 shares of the technology company's stock valued at $34,000 after acquiring an additional 3,031 shares in the last quarter. Parkside Financial Bank & Trust raised its position in shares of Evolent Health by 90.7% during the 4th quarter. Parkside Financial Bank & Trust now owns 4,957 shares of the technology company's stock valued at $56,000 after acquiring an additional 2,358 shares in the last quarter. Finally, AlphaCentric Advisors LLC acquired a new stake in shares of Evolent Health during the 4th quarter valued at approximately $61,000.

Insider Activity at Evolent Health

In related news, Director Brendan B. Springstubb purchased 5,000 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The shares were purchased at an average price of $8.75 per share, with a total value of $43,750.00. Following the purchase, the director now owns 11,842 shares of the company's stock, valued at $103,617.50. This trade represents a 73.08 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Seth Blackley bought 55,225 shares of the company's stock in a transaction dated Thursday, March 6th. The stock was purchased at an average cost of $9.01 per share, for a total transaction of $497,577.25. Following the completion of the transaction, the chief executive officer now owns 762,217 shares of the company's stock, valued at $6,867,575.17. This represents a 7.81 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 74,000 shares of company stock valued at $666,315 over the last 90 days. 1.60% of the stock is currently owned by corporate insiders.

Evolent Health Stock Performance

Shares of NYSE:EVH traded up $0.43 on Wednesday, hitting $9.08. The company's stock had a trading volume of 314,775 shares, compared to its average volume of 2,516,757. Evolent Health, Inc. has a 12 month low of $8.35 and a 12 month high of $33.63. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of -11.07 and a beta of 1.20. The stock's 50-day moving average is $9.59 and its two-hundred day moving average is $12.95. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04.

Evolent Health (NYSE:EVH - Get Free Report) last announced its earnings results on Thursday, February 20th. The technology company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.38 by ($0.35). Evolent Health had a negative net margin of 2.41% and a positive return on equity of 5.73%. The firm had revenue of $646.54 million for the quarter, compared to the consensus estimate of $650.92 million. On average, equities research analysts forecast that Evolent Health, Inc. will post 0.08 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Oppenheimer dropped their price target on Evolent Health from $28.00 to $18.00 and set an "outperform" rating on the stock in a research report on Friday, January 24th. Stephens dropped their target price on Evolent Health from $16.00 to $12.00 and set an "equal weight" rating on the stock in a research report on Tuesday, January 21st. Needham & Company LLC reaffirmed a "buy" rating and issued a $15.00 target price on shares of Evolent Health in a research report on Friday, February 21st. JPMorgan Chase & Co. dropped their target price on Evolent Health from $13.00 to $12.00 and set an "overweight" rating on the stock in a research report on Monday, March 10th. Finally, Royal Bank of Canada dropped their target price on Evolent Health from $20.00 to $17.00 and set an "outperform" rating on the stock in a research report on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Evolent Health currently has an average rating of "Buy" and an average price target of $17.64.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.